Genomic Health Inc. (GHDX) Insider Sells $89,040.00 in Stock
Genomic Health Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of Genomic Health stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $29.68, for a total transaction of $89,040.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
James J. Vaughn also recently made the following trade(s):
- On Monday, August 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $28.74, for a total transaction of $86,220.00.
Genomic Health Inc. (NASDAQ:GHDX) opened at 30.48 on Wednesday. The firm’s market capitalization is $1.02 billion. Genomic Health Inc. has a 52-week low of $20.05 and a 52-week high of $35.79. The firm has a 50-day moving average of $28.15 and a 200-day moving average of $27.27.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The firm had revenue of $81.97 million for the quarter, compared to analyst estimates of $81.27 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The company’s quarterly revenue was up 16.1% compared to the same quarter last year. On average, equities research analysts forecast that Genomic Health Inc. will post ($0.47) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of GHDX. Bank of Montreal Can purchased a new stake in Genomic Health during the second quarter valued at about $187,000. Royal Bank of Canada raised its stake in Genomic Health by 6,543.0% in the first quarter. Royal Bank of Canada now owns 8,503 shares of the company’s stock valued at $210,000 after buying an additional 8,375 shares during the period. AQR Capital Management LLC purchased a new stake in Genomic Health during the second quarter valued at about $270,000. American International Group Inc. raised its stake in Genomic Health by 3.2% in the second quarter. American International Group Inc. now owns 10,753 shares of the company’s stock valued at $278,000 after buying an additional 334 shares during the period. Finally, Nationwide Fund Advisors raised its stake in Genomic Health by 3.0% in the second quarter. Nationwide Fund Advisors now owns 11,932 shares of the company’s stock valued at $309,000 after buying an additional 351 shares during the period. 88.92% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages recently commented on GHDX. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Thursday, August 4th. Canaccord Genuity restated a “buy” rating and issued a $38.00 price target on shares of Genomic Health in a research report on Friday, August 5th. Leerink Swann restated a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Jefferies Group raised their price target on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Finally, Bank of America Corp. set a $28.00 price target on shares of Genomic Health and gave the stock a “sell” rating in a research report on Wednesday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $32.50.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.